Ceapro Inc (CZO)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ceapro Inc (CZO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012273
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ceapro Inc (Ceapro) is a biotechnology company which focuses on the development of extraction technology for use in the production of extracts and active ingredients from oats and other renewable plant resources. These extracts find application in therapeutic products for both humans and animals and cosmeceutical and nutraceutical industries. The company’s portfolio include natural active ingredients comprising oat avenanthramides, oat oil, oat peptides, oat beta glucan, and lupin peptides; and veterinary products including oat shampoo, ear cleanser and dermal complex/conditioner. The company along with its subsidiaries operates mainly in the US, Germany, China, Canada and other countries. Ceapro is headquartered in Edmonton, Alberta, Canada.

Ceapro Inc (CZO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ceapro Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Ceapro Expands Licensing Agreement with University of Alberta 10
Ceapro Enters into Licensing Agreement with University of Alberta 11
Symrise Enters Into Licensing Agreement With Ceapro 12
Equity Offering 13
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 13
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 15
Debt Offering 17
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 17
Ceapro Inc – Key Competitors 18
Ceapro Inc – Key Employees 19
Ceapro Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Nov 15, 2017: Ceapro Reports 2017 Third Quarter Business Update and Financial Results 21
Aug 18, 2017: Ceapro Reports 2017 Second Quarter Business Update and Financial Results 23
May 17, 2017: Ceapro Reports 2017 First Quarter Development Highlights and Financial Results 25
Apr 06, 2017: Ceapro Reports 2016 Financial Results and Provides Corporate Update 27
Nov 23, 2016: Ceapro Reports Third Quarter 2016 Financial and Operational Results 29
Aug 24, 2016: Ceapro Reports Second Quarter 2016 Financial and Operational Results 30
May 18, 2016: Ceapro Reports 2016 First Quarter Financial Results and Provides Corporate Update 31
Apr 14, 2016: Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company’s History 33
Legal and Regulatory 34
Feb 03, 2016: Ceapro Issued U.S. Patent for Enabling Pressurized Gas Expanded Technology 34
Government and Public Interest 35
Sep 21, 2016: Ceapro Awarded Research Grant from German-Canadian Centre for Innovation and Research 35
Other Significant Developments 36
Apr 18, 2016: Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Ceapro Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Ceapro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Ceapro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Ceapro Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Ceapro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Ceapro Expands Licensing Agreement with University of Alberta 10
Ceapro Enters into Licensing Agreement with University of Alberta 11
Symrise Enters Into Licensing Agreement With Ceapro 12
Ceapro Raises USD3.3 Million in Second and Final Tranche of Private Placement of Units 13
Ceapro Raises USD4.4 Million in First Tranche of Brokered Private Placement of Units 15
Ceapro Raises USD0.24 Million in Second Tranche of Private Placement of Debentures Due 2016 17
Ceapro Inc, Key Competitors 18
Ceapro Inc, Key Employees 19
Ceapro Inc, Subsidiaries 20

★海外企業調査レポート[Ceapro Inc (CZO)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Formycon AG (FYB):企業の財務・戦略的SWOT分析
    Summary Formycon AG (Formycon) formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs candidates. The company offers biopharmaceutical imitation products for global recovery. It provides four biosimilar products in pre-clinical and clinical testing phases. Formycon’s pipe …
  • Sumitomo Heavy Industries Construction Cranes Co., Ltd.
    Sumitomo Heavy Industries Construction Cranes Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Heavy Industries Construction Cranes Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Pinnacle West Capital Corporation (PNW):企業の財務・戦略的SWOT分析
    Pinnacle West Capital Corporation (PNW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Chromatin Inc:企業のM&A・事業提携・投資動向
    Chromatin Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chromatin Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • InVivoScribe Technologies Inc:企業の製品パイプライン分析
    Summary InVivoScribe Technologies Inc (InVivoScribe) is a provider of hematology-oncology testing products and services. The company offer full range of hematology-oncology testing products and services. It’s products include lymphotrack and lymphotrack DX assay kits, and custom assay and reagent de …
  • Alecta Pensionsforsakring Omsesidigt:企業の戦略的SWOT分析
    Alecta Pensionsforsakring Omsesidigt - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Valeant Canada LP:製薬・医療:M&Aディール及び事業提携情報
    Summary Valeant Canada LP (Valeant Canada), a subsidiary of Valeant Pharmaceuticals International Inc, is a pharmaceutical products manufacturing company. The company offers products such as aczone, airomir, aldara, benzaclin topical gel, benzamycin, biacna topical gel, C.E.S. tablets, carbolith, ca …
  • Grunenthal GmbH:企業の戦略的SWOT分析
    Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Vertical Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Vertical Pharmaceuticals LLC (Vertical Pharmaceuticals), a subsidiary of Osmotica Pharmaceutical Corp, is a medicines marketing company that supplies niche prescription medicines. The company offers product category includes women's health and pain management. It provides products such as Co …
  • Tianjin Zhonghuan Semiconductor Co Ltd (002129):企業の財務・戦略的SWOT分析
    Tianjin Zhonghuan Semiconductor Co Ltd (002129) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Thor Mining Plc (THR):企業の財務・戦略的SWOT分析
    Summary Thor Mining Plc (Thor Mining) is a mining and mineral exploration and development company. The company carries out acquisition, exploration and develops gold, tungsten and molybdenum properties. Its projects include Molyhil Tungsten and Molybdenum, Spring Hill Gold, Dundas Gold project, and …
  • DPR Construction Inc:企業の戦略的SWOT分析
    DPR Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • DS Smith Plc:企業のM&A・事業提携・投資動向
    DS Smith Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DS Smith Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Globus Medical Inc (GMED):医療機器:M&Aディール及び事業提携情報
    Summary Globus Medical Inc (Globus) is a medical device company which manufactures and markets musculoskeletal implants with focus on the treatment of spine disorders. The company’s product portfolio includes biomaterial products, cervical, deformity, intervertebral fusion, minimally invasive, motio …
  • Intrepid Mines Limited:企業の戦略・SWOT・財務情報
    Intrepid Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Intrepid Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Columbia Power Corp:企業の戦略的SWOT分析
    Columbia Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Aerosup Inc.:企業の戦略・SWOT・財務分析
    Aerosup Inc. - Strategy, SWOT and Corporate Finance Report Summary Aerosup Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • hVIVO Plc (HVO):製薬・医療:M&Aディール及び事業提携情報
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • eFFECTOR Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary eFFECTOR Therapeutics Inc (Effector) is a biopharmaceutical company that concentrates on new class of oncology drugs-selective translation regulators. The company works on the discovery and development of translation regulators as a new small molecule therapeutics that control gene expressio …
  • Universal Travel Group:企業の戦略・SWOT・財務分析
    Universal Travel Group - Strategy, SWOT and Corporate Finance Report Summary Universal Travel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆